Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12myotubes

Authors: Claudia L Yano, Gislaine Ventrucci, William N Field, Michael J Tisdale, Maria Cristina C Gomes-Marcondes

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Patients with advanced cancer suffer from cachexia, which is characterised by a marked weight loss, and is invariably associated with the presence of tumoral and humoral factors which are mainly responsible for the depletion of fat stores and muscular tissue.

Methods

In this work, we used cytotoxicity and enzymatic assays and morphological analysis to examine the effects of a proteolysis-inducing factor (PIF)-like molecule purified from ascitic fluid of Walker tumour-bearing rats (WF), which has been suggested to be responsible for muscle atrophy, on cultured C2C12 muscle cells.

Results

WF decreased the viability of C2C12 myotubes, especially at concentrations of 20–25 μg.mL-1. There was an increase in the content of the pro-oxidant malondialdehyde, and a decrease in antioxidant enzyme activity. Myotubes protein synthesis decreased and protein degradation increased together with an enhanced in the chymotrypsin-like enzyme activity, a measure of functional proteasome activity, after treatment with WF. Morphological alterations such as cell retraction and the presence of numerous cells in suspension were observed, particularly at high WF concentrations.

Conclusion

These results indicate that WF has similar effects to those of proteolysis-inducing factor, but is less potent than the latter. Further studies are required to determine the precise role of WF in this experimental model.
Appendix
Available only for authorised users
Literature
1.
Albrecht JT, Canada TW: Cachexia and anorexia in malignancy. Hematol Oncol Clin North Am. 1996, 10: 791-800. 10.1016/S0889-8588(05)70368-3.CrossRefPubMed
2.
3.
Costelli P, Baccino FM: Cancer cachexia: from experimental models to patient management. Curr Opin Clin Nutr Metab Care. 2000, 3: 177-181. 10.1097/00075197-200005000-00003.CrossRefPubMed
4.
Strelkov ABC, Fields ALA, Baracos VE: Effect of systemic inhibition of prostaglandin production on protein metabolism in tumour-bearing rats. Am J Physiol. 1989, 275: C261-269.
5.
6.
Strassmann G, Fong M, Freter CE, Windsor S, D'Alessandro F, Nordan RP: Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest. 1993, 925: 2152-2159.CrossRef
7.
Garcia-Martínez C, López-Soriano FJ, Argilés JM: Interleukin-6 does not active protein breakdoen in rat skeletal muscle. Cancer Lett. 1994, 76: 1-4. 10.1016/0304-3835(94)90126-0.CrossRefPubMed
8.
Matthys P, Billiau A: Cytokines and cachexia. Nutrition. 1997, 13: 763-770. 10.1016/S0899-9007(97)00185-8.CrossRefPubMed
9.
Todorov P, Cariuk P, Mc Devitt T, Coles B, Fearon KC, Tisdale MJ: Characterization of a cancer cachectic factor. Nature. 1996, 22: 739-742. 10.1038/379739a0.CrossRef
10.
Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ: Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer. 1997, 76: 606-613.CrossRefPubMedPubMedCentral
11.
Belizario JE, Kartz M, Chenker E, Raw I: Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma protein from cancer patients with weight loss. Br J Cancer. 1991, 635: 705-710.CrossRef
12.
Gomes-Marcondes MC, Smith HJ, Cooper JC, Tisdale MJ: Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor. Br J Cancer. 2002, 86: 1628-33. 10.1038/sj.bjc.6600236.CrossRefPubMedPubMedCentral
13.
Eley HL, Tisdale MJ: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J Biol Chem. 2007, 282: 7087-7097. 10.1074/jbc.M610378200.CrossRefPubMed
14.
Fujiki F, Mukaida N, Hirose K, Ishida H, Harada A, Ohno S, Bluethmann H, Kawakami M, Akiyama M, Sone S, Matsushima K: Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res. 1997, 57: 94-99.PubMed
15.
Todorov PT, Field WN, Tisdale MJ: Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer. 1999, 80: 1734-1737. 10.1038/sj.bjc.6690590.CrossRefPubMedPubMedCentral
16.
Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW: Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer. 2001, 84: 1599-1601. 10.1054/bjoc.2001.1830.CrossRefPubMedPubMedCentral
17.
Ushmorov A, Iiach V, Droge W: Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia. Cancer Res. 1999, 59: 3527-3534.PubMed
18.
Theologides A, Ingersoll-Stroubos AM, Apple FS: TNF-γ effect on oxygen free radical scavenging and generating enzymes in rat liver. Biochem Mol Biol Int. 1994, 33: 205-210.PubMed
19.
Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E: Experimental cancer cachexia: the role of host-derived cytokines interleukin IL;-6 IL-12 interferon-gamma and tumour necrosis factor alpha evaluated in gene knockout tumour-bearing mice on C57Bl background and eicosanoid-dependent cachexia. Cancer Res. 2000, 60: 5488-5493.PubMed
20.
Emery PW: Cachexia in experimental models. Nutrition. 1999, 15: 600-603. 10.1016/S0899-9007(99)00095-7.CrossRefPubMed
21.
Gomes-Marcondes MC, Honma HN, Áreas MA, Cury L: Effect of Walker 256 tumour growth on intestinal absorption of leucine methionine and glucose in newly weaned and mature rats. Braz J Med Biol Res. 1998, 31: 1345-1348.CrossRefPubMed
22.
Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed
23.
Mossman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.CrossRef
24.
Borenfreud G, Puerner JA: Toxicity determined in vitro by morphological alternatives and neutral red absorption. Toxicol Lett. 1995, 24: 110-124.
25.
Cinti MR, De Angelis I, Fortunati E, Reggiani D, Bianchi VV, Tiozzo R, Zucco F: Choice and standardisation of test protocols in cytotoxicology: a multicenter approach. Toxicol In Vitro. 1991, 5: 119-125. 10.1016/0887-2333(91)90031-8.CrossRef
26.
Habig WH, Pabst MJ, Jakoby WB: Glutathione S-transferases The first step in mercapturic acid formation. J Biol Chem. 1974, 249: 7130-7139.PubMed
27.
Gomes-Marcondes MC, Tisdale MJ: Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 2002, 180: 69-74. 10.1016/S0304-3835(02)00006-X.CrossRefPubMed
28.
White ME, Allen CE, Dayton WR: Effect of sera from fed and fasted pigs on proliferation and protein turnover in cultured myogenic cells. J Anim Sci. 1988, 66: 34-42.PubMed
29.
Gad SC, Weil CS: Statistics for toxicologists. Principles and Methods of Toxicoloy. Edited by: Wallace H. 1994, Raven Press New York, 221-274.
30.
Tisdale MJ: The 'cancer cachectic factor'. Support Care Cancer. 2003, 11: 73-78.PubMed
31.
Todorov PT, Deacon M, Tisdale MJ: Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem. 1997, 272: 12279-12288. 10.1074/jbc.272.19.12279.CrossRefPubMed
32.
Lundholm K, Bylund AC, Holm J, Schersten T: Skeletal muscle metabolism in patients with malignant tumour. Eur J Cancer. 1976, 12: 465-473.CrossRefPubMed
33.
Bossola M, Muscaritoli M, Costelli P: Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol. 2001, 280: R1518-1523.
34.
Williams A, Sun X, Fischer JE, Hasselgren P-O: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 1999, 126: 744-750.CrossRefPubMed
35.
Tisdale MJ: The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol. 2005, 3: 209-217.PubMed
36.
Siddiqui RA, Williams JF: The regulation of fatty acid and branched-chain aminoacid oxidation in cancer cachectic rats: A proposed role for a cytokine eicosanoid and hormone trilogy. Biochem Med Metab Biol. 1989, 42: 71-86. 10.1016/0885-4505(89)90043-1.CrossRefPubMed
37.
Siddiqui RA, Williams JF: Tentative identification of the toxohormones of cancer cachexia: roles of vasopressin prostaglandin E2 and cachectic-TNF. Biochem Int. 1990, 20: 787-797.PubMed
38.
Machado AP, Costa Rosa LF, Seelaender MC: Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res. 2004, 318: 503-514. 10.1007/s00441-004-0987-2.CrossRefPubMed
39.
Benitez-Verguizas J, Loarte D, de Miguel F, Esbrit P: Effects of transforming growth factor beta1 on cell growth and parathyroid hormone-related protein in Walker 256 tumor cells. Life Sci. 1999, 65: 1807-1816. 10.1016/S0024-3205(99)00437-3.CrossRefPubMed
40.
Deans DAC, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KCH, Ross JA: Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastro-oesophageal malignancy. Br J Cancer. 2006, 94: 731-736.PubMedPubMedCentral
41.
Seelaender MC, Nascimento CM, Curi R, Willians JF: Studies on lipid metabolism of Walker 256 tumour-bearing rats during the development of cancer cachexia. Biochem Mol Biol Int. 1996, 39: 1037-1047.PubMed
42.
Curi R, Fernandes LC, Razi SE, Boeckh-Haeisch EM, Machado UF, Guimarães ARP, Homem de Bittencourt PI, Carpinelli AR: The central role of insulin for the establishment of cachexia in Walker 256 tumour-bearing rats. Cancer Res Ther Control. 1999, 10: 109-118.
43.
Mahony SM, Tisdale MJ: Metabolic effects of tumour necrosis factor alpha in NMRI mice. Br J Cancer. 1990, 614: 514-519.CrossRef
44.
Baracos VE: Regulation of skeletal muscle protein turnover in cancer associated cachexia. Nutrition. 2000, 16: 1015-1018. 10.1016/S0899-9007(00)00407-X.CrossRefPubMed
45.
Yasmineh WG, Parkin JL, Caspers JI, Theologides A: Tumour necrosis factor/cachectin decreases catalase activity of rat liver. Cancer Res. 1991, 51: 3990-3995.PubMed
46.
Yamaguchi Y, Sato K, Endo H: Depression of catalase gene expression in the liver of tumour-bearing nude mice. Biochem Biophys Res Commun. 1992, 189: 1084-1089. 10.1016/0006-291X(92)92315-O.CrossRefPubMed
47.
Popadiuk S, Korzon M, Renke J, Wozniak M: Carbonyl groups content on the basis of protein peroxidation analysis with total antioxidant status in blood of children with cancers. Wiad Lek. 1998, 51: 107-112.PubMed
48.
Lo YYC, Cruz TF: Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem. 1995, 270: 11727-11730. 10.1074/jbc.270.20.11727.CrossRefPubMed
49.
Tang DG, Guan KL, Li L, Honn KV, Chen YQ, Rice RL, Taylor JD, Porter AT: Suppression of W256 carcinosarcoma cell apoptosis by arachidonic acid and other polyunsaturated fatty acids. Int J Cancer. 1997, 73: 1078-1087. 10.1002/(SICI)1097-0215(19970917)72:6<1078::AID-IJC24>3.0.CO;2-#.CrossRef
50.
Primeau AJ, Adhihetty PJ, Hood DA: Apoptosis in heart and skeletal muscle. Can J Appl Physiol. 2002, 27: 349-395.CrossRefPubMed
51.
Bar-Shai M, Reznick AZ: Reactive nitrogen species induce nuclear factor-κB-mediated protein degradation in skeletal muscle cells. Free Radical Biol Med. 2006, 40: 2112-2125. 10.1016/j.freeradbiomed.2006.02.009.CrossRef
52.
Wyke SM, Tisdale MJ: NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer. 2005, 92: 711-721. 10.1038/sj.bjc.6602402.CrossRefPubMedPubMedCentral
Metadata
Title
Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12myotubes
Authors
Claudia L Yano
Gislaine Ventrucci
William N Field
Michael J Tisdale
Maria Cristina C Gomes-Marcondes
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-24

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Dissemination of periodic mammography and patterns of use, by birth cohort, in Catalonia (Spain)

Research article

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Research article

Cancer incidence in men: a cluster analysis of spatial patterns

Research article

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis

Research article

MDM2 gene SNP309 T/G and p53gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians

Research article

P53 expression is significantly correlated with high risk of malignancy and epithelioid differentiation in GISTs. An immunohistochemical study of 104 cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits